News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 10, 2022 Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
June 7, 2022 Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
June 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2022 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
June 1, 2022 Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
May 12, 2022 Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
May 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2022 Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
May 4, 2022 Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
May 3, 2022 Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company